# Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/tocilizumab-versus-baricitinib-in-hospitalized-patients-with-severe-covid-19-an/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Τheodoros Karampitsakos,Ουρανία Παπαϊωάννου,Panagiota Tsiri,Matthaios Katsaras,Andreas Katsimpris,Andreas P. Kalogeropoulos,Elli Malakounidou,Eirini Zarkadi,Georgios Tsirikos,Vasiliki V. Georgiopoulou,Vasilina Sotiropoulou,Electra Koulousousa,Charikleia Chourpiliadi,Apostolos Matsioulas,Maria Lagadinou,Fotios Sampsonas,Karolina Akinosoglou,Markos Marangos,Αrgyris Τzouvelekis |
| Citations | 45 |
| DOI | 10.1016/j.cmi.2022.10.015 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.clinicalmicrobiologyandinfection.com/article/S1198743X22005298/pdf |
| OpenAlex ID | https://openalex.org/W4306889135 |
| PMID | 36273769 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Andreas Katsimpris](https://scholariq.org/researchers/andreas-katsimpris/)

## Paper primary topic

- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)

## Paper topics

- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Long-Term Effects of COVID-19](https://scholariq.org/topics/long-term-effects-of-covid-19/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.